Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jayne Antony is active.

Publication


Featured researches published by Jayne Antony.


Neurology | 2011

VGKC antibodies in pediatric encephalitis presenting with status epilepticus

Jehan Suleiman; Tanja Brenner; Deepak Gill; Fabienne Brilot; Jayne Antony; Angela Vincent; Bethan Lang; Russell C. Dale

Background: Voltage-gated potassium channel antibodies (VGKC Ab) are associated with limbic encephalitis and neuromyotonia in adults. There have been no systematic investigations in children to date. Methods: We looked for antibodies that are associated with CNS syndromes in adults including antibodies to VGKCs, NMDARs, glutamic acid decarboxylase (GAD), and glycine receptor (GlyR) in the stored acute serum from 10 children with unexplained encephalitis presenting with encephalopathy and status epilepticus. We also looked for antibodies to leucine-rich glioma-inactivated 1 (Lgi1) and contactin-associated protein-like 2 (Caspr2), which are now known to be tightly complexed with VGKCs in vivo. Sixty-nine pediatric controls were used for comparison. Results: An elevated VGKC Ab (>100 pM) was detected in 4/10 patients with encephalitis compared to only 1/69 controls (p < 0.001). The outcome in the 4 VGKC Ab-positive patients with encephalitis was variable including good recovery (n = 1), cognitive impairment (n = 3), temporal lobe epilepsy (n = 2), and mesial temporal sclerosis (n = 1). No other antibodies were detected, including those to Lgi1 and Caspr2. Conclusion: Encephalitis associated with VGKC Ab occurs in children and presents with status epilepticus and focal epilepsy. These antibodies are not directed against Lgi1 or Caspr2.


Brain | 2014

Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2

A. Reghan Foley; Manoj P. Menezes; Amelie Pandraud; Michael Gonzalez; Ahmad Al-Odaib; Alexander J. Abrams; Kumiko Sugano; Atsushi Yonezawa; Adnan Y. Manzur; Joshua Burns; Imelda Hughes; B. Gary McCullagh; Heinz Jungbluth; Ming Lim; Jean-Pierre Lin; André Mégarbané; J. Andoni Urtizberea; Ayaz H. Shah; Jayne Antony; Richard Webster; Alexander Broomfield; Joanne Ng; Ann Agnes Mathew; James J. O’Byrne; Eva Forman; M. Scoto; Manish Prasad; Katherine O’Brien; S. E. Olpin; Marcus Oppenheim

Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous group of disorders. A particularly severe subgroup first described in 1894, and subsequently called Brown-Vialetto-Van Laere syndrome, is characterized by progressive pontobulbar palsy, sensorineural hearing loss and respiratory insufficiency. There has been no treatment for this progressive neurodegenerative disorder, which leads to respiratory failure and usually death during childhood. We recently reported the identification of SLC52A2, encoding riboflavin transporter RFVT2, as a new causative gene for Brown-Vialetto-Van Laere syndrome. We used both exome and Sanger sequencing to identify SLC52A2 mutations in patients presenting with cranial neuropathies and sensorimotor neuropathy with or without respiratory insufficiency. We undertook clinical, neurophysiological and biochemical characterization of patients with mutations in SLC52A2, functionally analysed the most prevalent mutations and initiated a regimen of high-dose oral riboflavin. We identified 18 patients from 13 families with compound heterozygous or homozygous mutations in SLC52A2. Affected individuals share a core phenotype of rapidly progressive axonal sensorimotor neuropathy (manifesting with sensory ataxia, severe weakness of the upper limbs and axial muscles with distinctly preserved strength of the lower limbs), hearing loss, optic atrophy and respiratory insufficiency. We demonstrate that SLC52A2 mutations cause reduced riboflavin uptake and reduced riboflavin transporter protein expression, and we report the response to high-dose oral riboflavin therapy in patients with SLC52A2 mutations, including significant and sustained clinical and biochemical improvements in two patients and preliminary clinical response data in 13 patients with associated biochemical improvements in 10 patients. The clinical and biochemical responses of this SLC52A2-specific cohort suggest that riboflavin supplementation can ameliorate the progression of this neurodegenerative condition, particularly when initiated soon after the onset of symptoms.


Developmental Medicine & Child Neurology | 2012

Familial PRRT2 mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic migraine

Russell C. Dale; A Gardiner; Jayne Antony; Henry Houlden

PRRT2 is the gene recently associated with paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy, and choreoathetosis infantile convulsions. We report four family members with PRRT2 mutations who had heterogeneous paroxysmal disorders. The index patient had transient infantile paroxysmal torticollis, then benign infantile epilepsy that responded to carbamazepine. The index patient’s father had PKD and migraine with aphasia, and his two brothers had hemiplegic migraine with onset in childhood. All four family members had the same PRRT2 c.649dupC mutation. We conclude that heterogeneous paroxysmal disorders are associated with PRRT2 mutations and include paroxysmal torticollis and hemiplegic migraine. We propose that PRRT2 is a new gene for hemiplegic migraine.


Pediatrics | 2015

Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome

Sekhar Pillai; Yael Hacohen; Esther Tantsis; Kristina Prelog; Merheb; Alison Kesson; E.H. Barnes; Deepak Gill; Richard D. Webster; Manoj P. Menezes; Simone L. Ardern-Holmes; Sachin Gupta; Peter Procopis; Christopher Troedson; Jayne Antony; Robert Ouvrier; Polfrit Y; Davies Nw; P Waters; Bethan Lang; Ming Lim; Fabienne Brilot; Angela Vincent; Russell C. Dale

BACKGROUND AND OBJECTIVES: Pediatric encephalitis has a wide range of etiologies, clinical presentations, and outcomes. This study seeks to classify and characterize infectious, immune-mediated/autoantibody-associated and unknown forms of encephalitis, including relative frequencies, clinical and radiologic phenotypes, and long-term outcome. METHODS: By using consensus definitions and a retrospective single-center cohort of 164 Australian children, we performed clinical and radiologic phenotyping blinded to etiology and outcomes, and we tested archived acute sera for autoantibodies to N-methyl-D-aspartate receptor, voltage-gated potassium channel complex, and other neuronal antigens. Through telephone interviews, we defined outcomes by using the Liverpool Outcome Score (for encephalitis). RESULTS: An infectious encephalitis occurred in 30%, infection-associated encephalopathy in 8%, immune-mediated/autoantibody-associated encephalitis in 34%, and unknown encephalitis in 28%. In descending order of frequency, the larger subgroups were acute disseminated encephalomyelitis (21%), enterovirus (12%), Mycoplasma pneumoniae (7%), N-methyl-D-aspartate receptor antibody (6%), herpes simplex virus (5%), and voltage-gated potassium channel complex antibody (4%). Movement disorders, psychiatric symptoms, agitation, speech dysfunction, cerebrospinal fluid oligoclonal bands, MRI limbic encephalitis, and clinical relapse were more common in patients with autoantibodies. An abnormal outcome occurred in 49% of patients after a median follow-up of 5.8 years. Herpes simplex virus and unknown forms had the worst outcomes. According to our multivariate analysis, an abnormal outcome was more common in patients with status epilepticus, magnetic resonance diffusion restriction, and ICU admission. CONCLUSIONS: We have defined clinical and radiologic phenotypes of infectious and immune-mediated/autoantibody-associated encephalitis. In this resource-rich cohort, immune-mediated/autoantibody-associated etiologies are common, and the recognition and treatment of these entities should be a clinical priority.


Journal of Child Neurology | 2008

High-Dose Ribof lavin for Migraine Prophylaxis in Children: A Double-Blind, Randomized, Placebo-Controlled Trial

Suzanna C. MacLennan; Fiona M. Wade; Katharine M. L. Forrest; Pyara D. Ratanayake; Elizabeth Fagan; Jayne Antony

This is the first study to evaluate the efficacy of riboflavin for migraine prophylaxis in children. This was a randomized, double-blind study of riboflavin (200 mg daily) versus placebo in 48 children. The primary efficacy measure was the number of patients achieving a 50% or greater reduction in the number of migraine attacks per 4 weeks. Other outcome measures were the mean severity of migraine per day, mean duration of migraine, days with nausea or vomiting, analgesic use, and adverse effects. A 50% or greater reduction in headaches was seen in 14/21 patients in the placebo group and 12/27 patients in the riboflavin group (not significant P = .125). There were no differences between riboflavin and placebo for primary or secondary outcome variables. These results suggest that riboflavin is not an effective therapy for preventing migraine in children. A high placebo responder rate was seen, with implications for other studies of migraine in children.


Journal of Child Neurology | 2000

The Value of Partial Sleep Deprivation as a Routine Measure in Pediatric Electroencephalography

Sahas Liamsuwan; Padraic J. Grattan-Smith; Elizabeth Fagan; Andrew Bleasel; Jayne Antony

For more than 50 years it has been known that in patients with epilepsy, sleep markedly increases the diagnostic yield of the electroencephalogram (EEG). Sleep deprivation could have an additional activating role. Many laboratories do not use these methods routinely but reserve them for a second EEG if equivocal or negative findings are present in the initial EEG. We studied a regime of routine partial sleep deprivation without the use of hypnotic agents in 396 children younger than age 17 years who were referred for EEG with a diagnosis of epilepsy or suspected epilepsy. Sleep was achieved for the EEG in 77% (96% in the 1 month to 2 year age group, 78% in the 2 to 8 year age group, and in 64% of those more than 8 years old). In a comparison group of 72 children who had not been sleep-deprived, sleep was achieved in 44% (69% of those less than 2 years old, 27% of those between 2 and 8 years of age, and 33% of those older than 8 years). The differences were highly significant. The regime was well tolerated. Routine partial sleep deprivation is a practical and effective method of obtaining sleep and thus maximizing the information obtained from a single EEG. (J Child Neurol 2000;15:26-29).


Journal of Paediatrics and Child Health | 1991

Benign intracranial hypertension in childhood: A review of 23 patients

Robert A Ouvrier; I. Johnston; Peter G Procopis; Jayne Antony

Abstract  Twenty‐three patients with benign intracranial hypertension (BIH) were seen at the Royal Alexandra Hospital for Children, Sydney over an 18 year period to 1988. Age at presentation ranged from 6 months to 13 years and 5 months. The female to male ratio was 2.3: 1. The aetiological factors (sometimes multiple) included: chronic middle ear infection, 30%; dural sinus thrombosis, 22%; head injury, 13% Vitamin A overdosage, 4%; tetracycline exposure, 4%; and no apparent cause, 43%. Headache was the most common presenting symptom occurring in 91% of patients, followed by vomiting in 65% and blurred or double vision in 57%. Papilloedema occurred in 96% of patients, abducens palsy was noted in 48% and visual impairment in 45%. All patients improved clinically after treatment, one with lumbar puncture only. Of 17 patients treated with steroids, 10 patients recovered and seven patients went on to lumboperitoneal shunt. Two patients recovered with steroid and diuretic treatment. Of two patients initially treated with diuretics only, one recovered and one subsequently required a shunt. Only one patient was initially treated with a lumboperitoneal shunt. Three of the shunted patients had shunt block requiring revision. None had permanent visual loss or other significant sequelae.


Journal of Paediatrics and Child Health | 2003

Acute flaccid paralysis in Australian children.

Anne Morris; Elizabeth Elliott; Rennie D'Souza; Jayne Antony; Margery Kennett; H Longbottom

Objectives:  To describe the epidemiology and causes of acute flaccid paralysis (AFP) in Australian children, and the clinical features of the two most common causes of AFP, Guillain−Barré syndrome and transverse myelitis.


Epilepsia | 2012

Accelerated long-term forgetting in children with idiopathic generalized epilepsy

Michael B. Gascoigne; Belinda Barton; Richard Webster; Deepak Gill; Jayne Antony; Suncica Lah

Purpose:  The rapid forgetting of information over long (but not short) delays (accelerated long‐term forgetting [ALF]) has been associated with temporal lobe epilepsy but not idiopathic generalized epilepsy (IGE). Long‐term memory formation (consolidation) is thought to demand an interaction between medial temporal and neocortical networks, which could be disrupted by epilepsy/seizures themselves. The present study investigates whether ALF is present in children with IGE and whether it relates to epilepsy severity.


Developmental Medicine & Child Neurology | 2003

Peripheral neuropathies of infancy

Jo M. Wilmshurst; John D. Pollard; Garth A. Nicholson; Jayne Antony; Robert Ouvrier

Over a 33-year period, 260 patients (< 17 years of age; 119 males, 141 females) from New South Wales, Australia who had peripheral neuropathies confirmed by nerve biopsy, were studied. Of these, 50 infants presented with symptoms or signs of neuropathy under 1 year of age: including 24 patients with demyelinating neuropathies and 21 axonal neuropathies; a further five patients had spinal muscular atrophy with associated secondary sensory axonopathy. Nineteen infants had hereditary motor sensory neuropathy, of whom 13 had myelin protein mutations confirmed by molecular genetic studies. Peripheral neuropathy is not an unusual diagnosis in infancy. Awareness of this association will aid early diagnosis and prognosis as well as facilitate interventional patient management.

Collaboration


Dive into the Jayne Antony's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard Webster

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar

Robert Ouvrier

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar

Deepak Gill

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar

Monique M. Ryan

Royal Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Russell C. Dale

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar

Christopher Troedson

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar

Fabienne Brilot

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Katherine O’Brien

Children's Hospital at Westmead

View shared research outputs
Researchain Logo
Decentralizing Knowledge